Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

opioid crisis

  • Home
  •  
  • opioid crisis



  • Most Read
  • Latest Comments
  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    Mayne Pharma settles shareholder class action for $38M with no admission of guilt
    • News

  • Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    Vita Life Sciences reports sales growth of $4m as it launches in Vietnam
    • News

  • Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    Firebrick’s nasal hygiene spray launched in the US without FDA approvals
    • News

  • Amplia reports results from initial clinical trials of pancreatic cancer drug
    Amplia reports results from initial clinical trials of pancreatic cancer drug
    • News

  • Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?
    • News

    Palla Pharma blamed market conditions for their collapse. How did they sink in a billion dollar market?

    Opioid based medications are paradoxical. Whilst an incredible pharmacologic solution to serious pain, opioids can be addictive with their overuse often proving detrimental. America is often held up as the poster child for what not to do when it comes to their opioid epidemic which has seen more than 263,000 people die from prescription opioid

    Read More
    Public
  • Tackling the enduring epidemic taking place in the background of COVID-19
    • News

    Tackling the enduring epidemic taking place in the background of COVID-19

    With COVID dominating headlines for well over a year, you may not have noticed the worsening opioid crisis. Specifically in the United States where there has been a steep rise in overdose related deaths in the past 12 months. Data released by the National Centre for Health Statistics in July showed that in the year

    Read More
    Public
  • Medical Developments gains approval to commence Penthrox trials in China
    • News

    Medical Developments gains approval to commence Penthrox trials in China

    Australian pharmaceuticals manufacturer Medical Developments International (ASX: MVP) has secured approval from the Chinese National Medical Product Administration (NMPA) to commence bridging trials for Penthrox IND, their green whistle pain reliever.  The approval is a major step towards commercialisation of the flagship non-opioid pain reliever in China.  “The approval of the Penthrox IND by the

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.